RISING PHARMA HOLDINGS H-1B Visa Sponsorship & Salary Data

The median H-1B salary at RISING PHARMA HOLDINGS is $75,000, based on 22 certified filings from FY 2020 to FY 2026. This is 38% lower than the national H-1B median salary of $120,000. Compensation at RISING PHARMA HOLDINGS reflects their market positioning, with entry-level roles starting around $65,000 and senior positions reaching $150,000 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at RISING PHARMA HOLDINGS range from $60,549 at the 10th percentile to $150,000 at the 90th percentile, showing a $89,451 spread across experience levels and roles. The 25th percentile is $65,000 and the 75th percentile is $105,000.

Yes, RISING PHARMA HOLDINGS actively sponsors H-1B visas in FY 2026. In the most recent fiscal year (FY 2026), RISING PHARMA HOLDINGS filed 4 H-1B labor condition applications with 4 certified and 0 denied, at a median salary of $87,307. Across FY 2020–2026, they have filed 22 total H-1B applications with 22 certified and a 0% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. RISING PHARMA HOLDINGS sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2026), RISING PHARMA HOLDINGS filed 4 H-1B applications, with 4 certified and 0 denied. Over 3 years of data, RISING PHARMA HOLDINGS has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

RISING PHARMA HOLDINGS's LCA (Labor Condition Application) denial rate is 0%, with 0 out of 22 applications denied across all years. This translates to a 100.0% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating RISING PHARMA HOLDINGS as a potential H-1B sponsor.

This is an excellent approval rate, indicating RISING PHARMA HOLDINGS has strong H-1B sponsorship practices and typically meets DOL requirements. Applicants can feel confident in the company's H-1B track record.

RISING PHARMA HOLDINGS sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 22 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles RISING PHARMA HOLDINGS most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at RISING PHARMA HOLDINGS:

The most frequently sponsored role is Supply Chain Analyst with 3 filings at a median salary of $65,000. This is followed by Regulatory Affairs Specialist (2 filings) and IT Associate.

RISING PHARMA HOLDINGS's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where RISING PHARMA HOLDINGS sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top RISING PHARMA HOLDINGS H-1B locations:

The largest H-1B hub for RISING PHARMA HOLDINGS is East Brunswick, NJ with 14 filings at a median salary of $68,869. The highest-paying location is Decatur, IL at $75,000 median. Salaries range from $66,000 to $75,000 across office locations.

RISING PHARMA HOLDINGS's median H-1B salary has increased by +32% from FY 2020 ($66,000) to FY 2026 ($87,307). Tracking salary trends over time reveals how RISING PHARMA HOLDINGS adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at RISING PHARMA HOLDINGS.

Year-by-year breakdown:

• FY 2020: $66,000 (7 certified)
• FY 2025: $75,000 (11 certified)
• FY 2026: $87,307 (4 certified)

This 32% growth reflects strong compensation adjustments at RISING PHARMA HOLDINGS, keeping pace with market demands for H-1B talent.

RISING PHARMA HOLDINGS primarily files H-1B applications at Wage Level I, accounting for 57% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making RISING PHARMA HOLDINGS's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

A significant portion of RISING PHARMA HOLDINGS's H-1B filings are at entry-level (Level I) wages. These positions may face more competition in the H-1B lottery.

RISING PHARMA HOLDINGS's median H-1B salary of $75,000 is 38% lower than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating RISING PHARMA HOLDINGS's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare RISING PHARMA HOLDINGS's offerings with similar companies in your field for a more accurate assessment.

RISING PHARMA HOLDINGS's H-1B salaries are below the national median, though this may vary significantly by role, experience level, and location. Consider researching specific positions for more accurate compensation expectations.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. RISING PHARMA HOLDINGS files 57% of positions at Level I, which may face more lottery competition under wage-level prioritization rules.

With 22 certified filings, RISING PHARMA HOLDINGS invests significantly in H-1B sponsorship. The company's 0% denial rate suggests strong compliance with H-1B requirements and documentation standards.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.